• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.

作者信息

Yanagisawa Satoru, Morikawa Naoto, Kimura Yuichiro, Nagano Yoko, Murakami Kazuhiro, Tabata Toshiharu

机构信息

Department of Respiratory Medicine, Tohoku Kosei Nenkin Hospital, Sendai, Japan.

出版信息

Respirology. 2012 Nov;17(8):1275-7. doi: 10.1111/j.1440-1843.2012.02258.x.

DOI:10.1111/j.1440-1843.2012.02258.x
PMID:22943430
Abstract
摘要

相似文献

1
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.伴有表皮生长因子受体突变的大细胞神经内分泌癌：肺腺癌可能的转化形式
Respirology. 2012 Nov;17(8):1275-7. doi: 10.1111/j.1440-1843.2012.02258.x.
2
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.一名同时出现腺癌和小细胞肺癌且携带相同表皮生长因子受体（EGFR）第19外显子突变的患者。
Ann Oncol. 2012 Dec;23(12):3188-3189. doi: 10.1093/annonc/mds525. Epub 2012 Oct 18.
3
Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.携带EGFR突变的肺腺癌组织学转化为大细胞神经内分泌癌：一例尸检病例报告
Intern Med. 2017;56(15):2013-2017. doi: 10.2169/internalmedicine.56.7452. Epub 2017 Aug 1.
4
Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.携带表皮生长因子受体（EGFR）突变且对吉非替尼敏感的肺大细胞神经内分泌癌
J Clin Oncol. 2011 Dec 1;29(34):e819-22. doi: 10.1200/JCO.2011.36.2251. Epub 2011 Oct 31.
5
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.中药治疗可能对接受铂类化疗或联合靶向治疗与化疗的 IV 期肺腺癌患者的预后有一定影响。
Integr Cancer Ther. 2011 Jun;10(2):127-37. doi: 10.1177/1534735410387599. Epub 2010 Dec 8.
6
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.培美曲塞联合铂类与非培美曲塞联合铂类作为野生型表皮生长因子受体非鳞状非小细胞肺癌患者一线治疗的疗效比较：一项回顾性分析
Chemotherapy. 2016;61(1):41-50. doi: 10.1159/000440941. Epub 2015 Nov 1.
7
Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.纳武单抗联合紫杉醇对表皮生长因子受体（EGFR）突变型肺神经内分泌癌有显著反应：一例报告
Medicine (Baltimore). 2017 May;96(21):e6985. doi: 10.1097/MD.0000000000006985.
8
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.建立患者来源的非小细胞肺癌异种移植模型用于预测生物标志物的鉴定。
Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.
9
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.厄洛替尼联合培美曲塞治疗晚期非小细胞肺癌（NSCLC）患者：一项 I 期剂量探索研究。
Ann Oncol. 2010 Nov;21(11):2233-2239. doi: 10.1093/annonc/mdq246. Epub 2010 May 5.
10
Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.非小细胞肺癌中与厄洛替尼获得性耐药相关的向大细胞神经内分泌癌的转化
Korean J Intern Med. 2014 Nov;29(6):830-3. doi: 10.3904/kjim.2014.29.6.830. Epub 2014 Oct 31.

引用本文的文献

1
Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma.大细胞神经内分泌癌的一种亚型——联合大细胞神经内分泌癌的临床特征及治疗管理
Front Oncol. 2024 Oct 22;14:1449490. doi: 10.3389/fonc.2024.1449490. eCollection 2024.
2
Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review.ALK 阳性非小细胞肺癌中谱系可塑性的生物学特性及影响：一篇综述
Transl Lung Cancer Res. 2023 Apr 28;12(4):837-856. doi: 10.21037/tlcr-22-867. Epub 2023 Mar 22.
3
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.
癌基因依赖型非小细胞肺癌的形态-分子转化。
Int J Mol Sci. 2022 Apr 9;23(8):4164. doi: 10.3390/ijms23084164.
4
Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases.非小细胞肺癌的组织学转化：9例临床分析
World J Clin Cases. 2021 Jun 26;9(18):4617-4626. doi: 10.12998/wjcc.v9.i18.4617.
5
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities.肺大细胞神经内分泌癌：当前的治疗选择及未来潜在机遇
Front Oncol. 2021 Apr 15;11:650293. doi: 10.3389/fonc.2021.650293. eCollection 2021.
6
[Mechanism of Histologic Transformation of Drive Gene Positive Lung Adenocarcinoma in Targeted Therapy and Treatment Strategy].[驱动基因阳性肺腺癌在靶向治疗中的组织学转化机制及治疗策略]
Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):701-709. doi: 10.3779/j.issn.1009-3419.2020.102.22. Epub 2020 Aug 6.
7
Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease.一名非小细胞肺癌患者在从AC0010诱导的间质性肺病恢复后出现获得性EGFR T790M突变，使用奥希替尼成功治疗及其后续耐药机制
Onco Targets Ther. 2019 Jul 10;12:5545-5549. doi: 10.2147/OTT.S204689. eCollection 2019.
8
Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.获得性表皮生长因子酪氨酸激酶抑制剂耐药后的组织学转化。
Int J Clin Oncol. 2018 Apr;23(2):235-242. doi: 10.1007/s10147-017-1211-1. Epub 2017 Nov 7.
9
Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.携带EGFR突变的肺腺癌组织学转化为大细胞神经内分泌癌：一例尸检病例报告
Intern Med. 2017;56(15):2013-2017. doi: 10.2169/internalmedicine.56.7452. Epub 2017 Aug 1.
10
Treatment of lung large cell neuroendocrine carcinoma.肺大细胞神经内分泌癌的治疗。
Tumour Biol. 2016 Jun;37(6):7047-57. doi: 10.1007/s13277-016-5003-4. Epub 2016 Mar 4.